Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variantsArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] addition adenoviral vector Adenovirus adenovirus type 5 vector vaccine Anti-RBD IgG booster COVID-19 COVID-19 vaccine D614G demonstrated dose effective Efficacy IgA immunization Inactivated vaccine Inactivated Vaccines Inhaled lack mucosal Neutralization assay Neutralizing neutralizing antibody omicron Omicron variant BA.5 pandemic plasma Protective RBD SARS-CoV-2 SARS-CoV-2 pseudovirus SARS-CoV-2 vaccines SARS-CoV-2 variant subunit titre Vaccination strategies vaccination strategies. Vaccination strategy Vaccine variant virus widespread [DOI] 10.1080/22221751.2022.2132881 PMC 바로가기
Preclinical efficacy and safety of novel SNAT against SARS-CoV-2 using a hamster modelArticle Published on 2022-12-012022-11-15 Journal: Drug delivery and translational research [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome antioxidant Antiviral antiviral drug Antiviral drug candidate assays Body weight loss coronavirus COVID-19 demonstrated Efficacy Efficacy and safety Epidemic fibroblast global public health hamsters Health Histopathology human cells human lung epithelium IMPROVE Inhaled inhaler LDH lipid peroxidation lung MDA Nanotechnology oral swabs other respiratory virus pandemic platform Preclinical reduce SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-infected hamsters silver nanoparticle SmaRT SNAT. tested virus load virus titer [DOI] 10.1007/s13346-022-01166-x PMC 바로가기
Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysisArticle Published on 2022-12-012022-11-15 Journal: Drug Delivery [Category] COVID19(2023년), SARS, 치료제, [키워드] addition administration Analysis Antiviral antiviral activity Calu-3 Cell characterized Concentration COVID-19 cytotoxicity Favipiravir in vitro indicated Influenza virus Inhaled inhaled formulation inhibitor investigated lung lung epithelial cell lung tissue Lungs media Patient patients with COVID-19 PBS phosphate buffer profile pulmonary RdRP real time required respiratory. RNA-dependent RNA polymerase SARS-CoV-2 stability target Toxicity treat Treatment VERO-E6 viability were infected [DOI] 10.1080/10717544.2022.2118398 PMC 바로가기
Case Report: A 29-Year-Old Pregnant Woman at 24 Weeks of Gestation Presenting with Laryngotracheitis and COVID-19 Due to the R.1 Variant of SARS-CoV-2Article Published on 2022-10-182022-11-16 Journal: The American journal of case reports [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome Admission Adults adverse effect causes coronavirus Corticosteroid Corticosteroids cough COVID-19 discharge discharged disease E484K mutation edema Fever gestation healthy hospital Hospitalized Inhaled laryngotracheitis Lower respiratory tract nebulized oxygen saturation PCR polymerase chain positive Pregnancy Pregnant woman pregnant women presenting primary care SARS-CoV-2 severe disease course sore throat Symptom Symptoms treated Treatment variant of SARS-CoV-2 Week with COVID-19 woman Wuhan, China [DOI] 10.12659/AJCR.937834 PMC 바로가기
Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence TaskforceArticle Published on 2022-10-032022-11-15 Journal: The Medical journal of Australia [Category] COVID19(2023년), SARS, 진단, [키워드] Analysis anticoagulation Antiviral agents Baricitinib benefit change clinical clinical trial Combination coronavirus disease Corticosteroids COVID-19 disease disease severity drug treatment eight Endotracheal intubation Evidence facilitated Health include Inhaled maintain management Mild molnupiravir nine Patient people with COVID-19 positive airway pressure Primary Health Care prone positioning Prophylactic Prophylaxis Public public health. randomised recommendation recommendations Remdesivir Respiratory Support sarilumab subsequent supplemental oxygen Support supportive care systemic corticosteroids therapy Tocilizumab Treatment trials Venous Thromboembolism with COVID-19 [DOI] 10.5694/mja2.51718 PMC 바로가기
Evaluation of Continuous Inhaled Epoprostenol in the Treatment of Acute Respiratory Distress Syndrome, Including Patients With SARS-CoV-2 InfectionArticle Published on 2022-10-012023-07-07 Journal: The Annals of Pharmacotherapy [Category] COVID19(2023년), [키워드] ARDS Epoprostenol Inhaled prostacyclin pulmonary vasodilator. SARS-CoV-2 [DOI] 10.1177/10600280211069182 PMC 바로가기
Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trialArticle Published on 2022-09-202022-11-16 Journal: Trials [Category] SARS, 변종, [키워드] acute lung injury acute respiratory distress addition adverse effects antibody applied ARDS Aviptadil baseline Clinical improvement clinical status Concentration conducted COVID-19 COVID-19 in patient COVID-19 patient defined double-blinded Efficacy and safety Europe exclusion criteria FIVE hemodynamic instability high risk homeostasis hospital discharge Hospitalization immunomodulating IMPROVE indicate Inhaled intensive care intestinal intravenously lung lung tissue management mechanical ventilation metabolism Mortality multicenter Multicenter trial pandemic Pathways Patient patients hospitalized peptide placebo-controlled Prevent primary endpoint pro-inflammatory Prognosis Protein Public Hospital Randomized randomized trial Randomly reduction Regulation respiratory complication Risk factors SARS-CoV-2 severe disease course shown standard care stratified Study protocol suggested syndrome the SARS-CoV-2 therapeutic agent Therapies therapy Treatment unique vaccination Vaccine variants of SARS-CoV-2 Vasoactive VIP VIP. with COVID-19 World Health Organization [DOI] 10.1186/s13063-022-06723-w PMC 바로가기
Environmental contributions to the interactions of COVID-19 and asthma: a secondary publication and updateReview article Published on 2022-09-012022-10-05 Journal: The World Allergy Organization Journal [Category] 바이오마커, 치료기술, [키워드] addition allergens allergic rhinitis allergies association Asthma biological property caused change changed changes in children China conditions coronavirus 2 coronavirus disease COVID-19 COVID-19 pandemic current Diagnosis Effect Evidence explain extension implementation increase in Inflammation Inhaled intensity Interaction Isolation lockdown non-allergic outbreak outcomes pandemic Patient Phenotypes physical provoke reduce reduction respiratory risk risk factor SARS-CoV-2 severe COVID-19 severe disease Spread transmission rate transported triggered Type variable with COVID-19 worsening Wuhan [DOI] 10.1016/j.waojou.2022.100686 [Article Type] Review article
Carbon dioxide rises beyond acceptable safety levels in children under nose and mouth covering: Results of an experimental measurement study in healthy childrenRandomized Controlled Trial Published on 2022-09-012022-10-04 Journal: Environmental research [Category] 임상, [키워드] age ambient Appropriate automated average baseline breathing breathing frequency carbon carbon dioxide children CO(2) country covariate COVID-19 determine European face Face masks Health healthy children Inhaled Linear model Mask nose not significant pandemic physiological PPM provided pulse raise Randomized Randomized study. resting position Result seated sequence significant effect Spa Standard deviation surgical variables Ventilation was measured wearing were measured [DOI] 10.1016/j.envres.2022.113564 PMC 바로가기 [Article Type] Randomized Controlled Trial
Inhaled therapy for COVID-19: Considerations of drugs, formulations and devicesCOVID-19에 대한 흡입 요법: 약물, 제형 및 장치에 대한 고려 사항Review Published on 2022-08-252022-09-11 Journal: International journal of pharmaceutics [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Administered administration anti-SARS-CoV-2 antiviral drug antiviral drugs Antiviral treatment approach Clinical studies Combinational Concentration coronavirus COVID-19 COVID-19 pandemic Device disease dose drug drug combination drug susceptibility drugs effective effective vaccine Efficacy etiological agent include Infection inhalation Inhaled intravenous key consideration limitations lower dose lung majority mono potency preclinical studies reduce reduced responsible SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown Side effects tested therapy Treatment treatment for COVID-19 Treatment. [DOI] 10.1016/j.ijpharm.2022.122042 PMC 바로가기 [Article Type] Review